Biotech officials often point to the case of problems resulting from a generic version of Johnson & Johnson's Eprex drug as evidence problems can arise from allowing cheaper versions of biotech drugs. Unlike most drugs, these medicines use bioengineered cells, which can produce different results upon duplication. Generic drug makers say they recognize the problem and are looking for safe ways to copy biotech drugs and reduce the approval process. The FDA is also drafting scientific guidelines to address this issue.
Published in Brief: